809 related articles for article (PubMed ID: 9430476)
1. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
3. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
[TBL] [Abstract][Full Text] [Related]
4. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
[TBL] [Abstract][Full Text] [Related]
6. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
8. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
Wong JY; Somlo G; Odom-Maryon T; Williams LE; Liu A; Yamauchi D; Wu AM; Yazaki P; Wilczynski S; Shively JE; Forman S; Doroshow JH; Raubitschek AA
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
10. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
11. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice.
Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD
Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
14. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
Foss FM; Raubitscheck A; Mulshine JL; Fleisher TA; Reynolds JC; Paik CH; Neumann RD; Boland C; Perentesis P; Brown MR; Frincke JM; Lollo CP; Larson SM; Carrasquillo JA
Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
[TBL] [Abstract][Full Text] [Related]
18. Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Yazaki PJ; Sherman MA; Shively JE; Ikle D; Williams LE; Wong JY; Colcher D; Wu AM; Raubitschek AA
Protein Eng Des Sel; 2004 May; 17(5):481-9. PubMed ID: 15316127
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
